会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明专利
    • Drug for controlling labor pain and treating premature birth
    • 用于控制劳动者疼痛和治疗预期生殖的药物
    • JP2009269823A
    • 2009-11-19
    • JP2008118908
    • 2008-04-30
    • P-Lap:Kk株式会社 P−Lap
    • MIZUTANI EIHIKOTSUJIMOTO MASAFUMI
    • A61K38/00A61K38/46A61P15/06
    • A61K38/4813C12Y304/11003
    • PROBLEM TO BE SOLVED: To provide an ideal drug for controlling labor pain and treating premature birth which can adjust initiation of labor pain to control the term of delivery, is effective for a patient of premature birth, and does not adversely affect a fetus when administered.
      SOLUTION: An expression plasmid is obtained by connecting a cDNA which codes ORF of soluble form of human P-LAP to the Hind III site of a pdKCR-dhfr vector. Then, gene introduction into Chinese hamster ovary(CHO)-dhfr-cells is performed utilizing this expression plasmid. Thereafter, the gene-introduced cells are maintained in an α-mineral essential medium, and then a resistant clone is selected, and the resistance clone is multiplied to obtain a predetermined amount of a soluble form of P-LAP. Subsequently, when the obtained P-LAP is administered to a pregnant mouse to count the period between pregnancy and childbirth, it has been found that the administration of P-LAP tends to extend the period of pregnancy.
      COPYRIGHT: (C)2010,JPO&INPIT
    • 要解决的问题:提供一种理想的药物,用于控制劳动痛苦和治疗早产,可以调节劳动疼痛的开始以控制输送期,对早产儿有效,并且不会对 胎儿施用时。 解决方案:通过将编码人类P-LAP的可溶形式的ORF的cDNA连接到pdKCR-dhfr载体的HindIII位点来获得表达质粒。 然后,使用该表达质粒进行中国仓鼠卵巢(CHO)-dhfr-细胞的基因导入。 然后,将导入了基因的细胞保持在α-矿物质必需培养基中,然后选择抗性克隆,并且使抗性克隆相乘以获得预定量的可溶形式的P-LAP。 随后,当将获得的P-LAP施用于怀孕小鼠以计数怀孕与分娩期间时,发现P-LAP的给药倾向于延长怀孕期。 版权所有(C)2010,JPO&INPIT